封面
市场调查报告书
商品编码
1554287

3D 列印药品市场规模、份额和成长分析:按剂型、技术类型、应用和地区 - 产业预测,2024-2031 年

3D Printed Drugs Market Size, Share, Growth Analysis, By Dosage Form (Tablet, Capsule), By Technology Type (Inkjet Printing, Direct Write), By Application (Orthopedic, Neurology), By Region - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球3D列印药品市场规模为8,490万美元,从2023年的9,850万美元成长到2031年的3.2291亿美元,预计在预测期内(2024-2031年)复合年增长率为16%。

全球3D列印药品市场在製药领域正经历快速成长。这项技术越来越多地被用来生产定製药物配方、提高药物疗效、最大限度地减少副作用并实现个人化剂量。药品製造中的 3D 列印在基材上逐层列印精确剂量的药物,提供更个人化的治疗方法。北美市场领先,其次是欧洲和亚太地区。推动这一增长的关键因素包括对个人化医疗的需求不断增长、3D 列印提供的精确性和减少的副作用以及持续的技术进步。 3D 列印製药市场的主要目标是引入创新的药物製造方法,以改善患者的治疗效果并降低医疗成本。 3D列印技术使药物设计更加灵活,最大限度地减少浪费,并促进按需生产。儘管有这些优势,3D列印技术仍面临高成本和药物核准监管障碍等挑战。其他挑战包括需要进一步研究以确保安全性和有效性、印刷过程的标准化以及潜在的智慧财产权衝突。然而,市场上也存在重大机会,包括新配方的开发、新地区的扩张以及药物输送和个人化医疗转型的潜力。该技术还有可能为製药公司创造新的收益来源。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 二手资料来源和主要资料来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 市场成功因素
  • 价值链分析
  • 主要投资机会
  • 市场魅力指数
  • 生态系绘图
  • 价格分析
  • 价值链分析
  • 专利分析
  • 监管分析
  • 波特五力分析

3D列印药品市场:按剂型

  • 市场概况
  • 锭剂
  • 胶囊
  • 多重植入
  • 奈米粒子
  • 解决方案
  • 其他产品

3D列印製药市场:依技术类型

  • 市场概况
  • 喷墨印刷
  • 直接写入
  • 拉炼剂量
  • 热感喷墨列印
  • 熔融沈积法
  • 粉红床印刷
  • 立体光刻技术(SLA)
  • 半固体挤出(SSE)

3D列印医药市场:依应用分类

  • 市场概况
  • 整形外科
  • 神经病学
  • 牙科
  • 其他的

3D 列印药品市场规模:按地区

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位(2023年)
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率(2023年)

主要企业简介

  • Aprecia Pharmaceuticals, LLC(US)
  • FabRx Ltd(UK)
  • Cycle Pharmaceuticals(UK)
  • GlaxoSmithKline plc(UK)
  • AstraZeneca(UK/Sweden)
  • Tvasta(India)
  • Merck KGaA(Germany)
  • Terumo Corporation(Japan)
  • Extend Biosciences(US)
  • BioDuro(US)
  • Affinity Therapeutics(US)
  • Osmotica Pharmaceuticals(US)
  • Pfizer(US)
  • Sanofi(France)
  • 3D Systems(US)
  • BASF(Germany)
  • Teva Pharmaceuticals(Israel)
  • Novartis(Switzerland)
  • Roche(Switzerland)
  • Catalent(US)
  • Johnson & Johnson(US)
  • Vertex Pharmaceuticals(US)
  • Boehringer Ingelheim(Germany)
  • Siemens Healthineers(Germany)
  • Sandoz International(Germany)
  • BioBots(US)
  • Apium Additive Technologies(Germany)
  • Boston Micro Fabrication(US)
简介目录
Product Code: SQMIG35I2140

Global 3D Printed Drugs Market size was valued at USD 84.9 Million in 2022 and is poised to grow from USD 98.50 Million in 2023 to USD 322.91 Million by 2031, at a CAGR of 16% during the forecast period (2024-2031).

The global market for 3D-printed drugs is experiencing rapid growth within the pharmaceutical sector. This technology is increasingly utilized to produce customized drug formulations, enhancing drug effectiveness, minimizing side effects, and enabling personalized dosing. 3D printing in drug manufacturing involves the layer-by-layer creation of precise doses of medication on a substrate, offering a more tailored approach to treatment. North America leads the market, followed by Europe and Asia Pacific. Key factors driving this growth include the rising demand for personalized medicine, the precision and reduced side effects afforded by 3D printing, and ongoing technological advancements. The main objectives of the 3D-printed drugs market are to introduce innovative drug manufacturing methods that enhance patient outcomes and lower healthcare costs. 3D printing technology enables more flexible drug design, minimizes waste, and facilitates on-demand production. Despite these advantages, the market faces challenges such as high costs associated with 3D printing technology and regulatory hurdles for drug approval. Additional challenges include the need for further research to ensure safety and efficacy, standardization of printing processes, and potential intellectual property conflicts. However, the market also holds significant opportunities, such as the development of novel drug formulations, expansion into new regions, and the potential transformation of drug delivery and personalized medicine. This technology could also open new revenue streams for pharmaceutical companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global 3D Printed Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global 3D Printed Drugs Market Segmental Analysis

The global 3D printed drugs market is segmented based on dosage form, technology, application, and region. Based on technology, the market is segmented into Inkjet Printing, Direct Write, Zip Dose, Thermal Inkjet Printing, Fused Deposition Modelling, Powder Bed Printing, Stereolithography (SLA) and Semi Solid Extrusion (SSE). Based on application, the market is segmented into orthopedics, neurology, dental, and others. Based on dosage form, the market is segmented into Tablet, Capsule, Multidrug Implant, Nanoparticles, Solutions and Other Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and MEA.

Drivers of the Global 3D Printed Drugs Market

The global market for 3D-printed drugs is being significantly driven by the growing demand for personalized medicines. These medicines, tailored to individual patients based on their genetic, environmental, and lifestyle factors, offer numerous benefits over conventional drugs, such as enhanced efficacy, fewer side effects, and better patient adherence. 3D printing technology plays a crucial role in this sector by enabling the production of customized drug formulations with precise dosing and specific drug release profiles. This technology allows for the creation of drug products with unique geometries and formulations that traditional manufacturing methods cannot achieve. The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, further fuels the demand for personalized medicines. Such conditions often require ongoing treatment, and personalized drugs can significantly improve patient outcomes and overall quality of life. By facilitating targeted drug delivery, 3D printing can reduce the necessary dosage, thereby minimizing side effects and enhancing patient compliance. As both the demand for personalized medications and advancements in 3D printing technology continue to grow, the global 3D-printed drugs market is anticipated to expand rapidly in the coming years.

Restraints in the Global 3D Printed Drugs Market

he substantial initial investment needed for 3D printing equipment, software, and materials poses a significant challenge for small and medium-sized pharmaceutical companies looking to adopt this technology. The high costs associated with these resources can make 3D printing less accessible for many companies, limiting their ability to participate in the market. Additionally, the cost per unit for 3D-printed drugs tends to be higher compared to traditional drugs, primarily due to the expensive materials and the intricate production process involved. This higher cost can make 3D-printed medications less affordable for patients, potentially diminishing their market demand. Moreover, the regulatory landscape for 3D-printed drugs is still evolving, with approval processes often being both lengthy and costly. This regulatory uncertainty can further drive up the costs associated with 3D-printed drugs and restrict their availability to patients. As a result, the combination of high production costs and regulatory challenges can limit the widespread adoption and accessibility of 3D-printed pharmaceuticals.

Market Trends of the Global 3D Printed Drugs Market

The increasing collaboration between pharmaceutical companies and 3D printing firms is significantly advancing the global 3D Printed Drugs market. This partnership is accelerating innovation and expediting the development and market entry of new drugs and drug delivery systems. By working together, pharmaceutical companies and 3D printing specialists are leveraging the technology's capabilities to create complex and customized drug formulations with precise dosing and tailored characteristics. These collaborations are not only streamlining the development process but are also contributing to faster market introductions of novel drug products and delivery mechanisms. As this trend continues, it is expected to drive further growth in the 3D printed drugs sector, enhancing the industry's ability to meet evolving medical needs and patient preferences in the coming years.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors of The Market
  • Value Chain Analysis
  • Top Investment Pockets
  • Market Attractive Index
  • Ecosystem Mapping
  • Pricing analysis
  • Value chain analysis
  • Patent analysis
  • Regulatory analysis
  • Porter's five forces analysis

Global 3D Printed Drugs Market by Dosage Form

  • Market Overview
  • Tablet
  • Capsule
  • Multidrug Implant
  • Nanoparticles
  • Solutions
  • Other Products

Global 3D Printed Drugs Market by Technology Type

  • Market Overview
  • Inkjet Printing
  • Direct Write
  • Zip Dose
  • Thermal Inkjet Printing
  • Fused Deposition Modelling
  • Powder Bed Printing
  • Stereolithography (SLA)
  • Semi Solid Extrusion (SSE)

Global 3D Printed Drugs Market by Application

  • Market Overview
  • Orthopedic
  • Neurology
  • Dental
  • Others

Global 3D Printed Drugs Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Aprecia Pharmaceuticals, LLC (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • FabRx Ltd (UK)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Cycle Pharmaceuticals (UK)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • GlaxoSmithKline plc (UK)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • AstraZeneca (UK/Sweden)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Tvasta (India)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Merck KGaA (Germany)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Terumo Corporation (Japan)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Extend Biosciences (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • BioDuro (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Affinity Therapeutics (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Osmotica Pharmaceuticals (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Pfizer (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Sanofi (France)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • 3D Systems (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • BASF (Germany)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Teva Pharmaceuticals (Israel)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Novartis (Switzerland)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Roche (Switzerland)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Catalent (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Johnson & Johnson (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Vertex Pharmaceuticals (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Boehringer Ingelheim (Germany)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Siemens Healthineers (Germany)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Sandoz International (Germany)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • BioBots (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Apium Additive Technologies (Germany)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments
  • Boston Micro Fabrication (US)
    • Company overview
    • Business segment overview
    • Financial updates
    • Key developments